Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ociperlimab + Tislelizumab in Advanced TNBC
NCT05809895Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Sep 2023
- Primary completion
- Jul 2029
- Modality
- IgG Antibodies, Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of ociperlimab in triple-negative breast cancer (TNBC), sponsored by Novartis. Planned start Sep 2023; status: withdrawn.
02
Drugs
ociperlimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05809895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05809895.